Losatuxizumab vedotin (ABBV-221) is a second-generation antibody–drug conjugate (ADC) anti-EGFR that obtained some responses in a multicenter phase 1 study also enrolling patients with HNSCC, but it was poorly tolerated for the high frequency of infusion reactions [11]. Here, EGFR is linked to head and neck squamous cell carcinoma.